Trial: 202001128

A phase I/Ib, open-label, multi-center, study of KAZ954 as a single agent and in combination with Spartalizumab, NZV930 and NIR178 in patients with advanced solid tumors


Early Phase I (Cancer Control)

Principal Investigator

Park, Haeseong

Disease Site

Colon; Esophagus; Liver; Other Digestive Organ; Pancreas; Rectum; Stomach

Learn more about this study at: